Clinical Trial Search

Primary: Percentage of Participants With Late Grade 3-5 Genitourinary (GU) and Gastrointestinal (GI) Adverse Events (AE) at 18 Months — 2.56 percentage of participants — p=<0.0001

Primary: Overall Survival — 88.5; 88.1 percentage of participants — p=0.98

Primary: Five-year Disease-free Survival (DFS) Rate — 85.3; 86.3 percentage of participants — p=<0.001

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…

Primary: Overall Survival (12-year Rates Reported) — 71.3; 76.3 percentage of participants — p=0.020

Primary: Toxicity — 2; 0 Events

Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants

Primary: Number of Participants With Stable, Decreased, or Increased PSA Doubling Times (PSADT) — 7; 2; 17 Participants

Primary: Disease-specific Survival (DSS) (10-year Rates Reported) — 95; 96 percentage of participants — p=0.45

Primary: Overall Survival — 5.8; 5.1 years — p=0.15

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Number of Participants Free From Progression at 3 Years — 54 participants

Primary: Overall Survival Rate (10-year) — 61.9; 56.8 percentage of patients — p=0.0309

Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…

Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…

Primary: Prostate-Specific Antigen (PSA) Response — 14 participants

Primary: Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10…

Primary: Overall Survival (5-year Rate Reported) — 84.9; 87.2 percentage of participants — p=0.81

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Number of Participants With Progression-Free Survival — 66; 84 Participants — p=0.40

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Time to Objective Disease Progression — 11.7; 10.0 Weeks — p=0.052

Primary: Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence. — 30 participants

Primary: Treatment Tolerance (Genitourinary [GU] or Gastrointestinal [GI] Adverse Events) — 3 events

Primary: Progression-free Survival — 13 months

Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events

Primary: Number of Patients Experiencing Dose-Limiting Toxicities — 1; 1; 0 Participants

Primary: Acute Grade 3 or Higher Treatment-related Toxicity Rate. — 1; 3 participants — p=<0.0001

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants